

NovoSeven RT

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name:		Date:	
Patient's ID:		Patient's Date of Birth:	
Physician's Name:			
Specialty:		NPI#:	
Physician Office Telephone:		Physician Office Fax:	
Referring Provider Info: 🗖 Same as Re	equesting Provide	er	
Name:		NPI#:	
Fax:		Phone:	
Rendering Provider Info: 🗆 Same as Re	eferring Provide	□ Same as Requesting Provider	
Name:		• •	
Fax:		Phone:	
Required Demographic Information: Patient Weight:	kg		
Patient Height:	cm		
Please indicate the place of service for the	requested drug:		
	☐ Home	☐ Off Campus Outpatient Hospital	
☐ On Campus Outpatient Hospital	□ Office		
Drug Information:			
Strength/Measure			
		Units □ ml □ Gm □ mg □ ea □ Un	
Directions(sig)		_	

<u>Criteria Questions:</u>
What is the ICD-10 code?
 1. What is the diagnosis? □ Congenital factor VII deficiency, Continue to 3 □ Hemophilia A, Continue to 2 □ Hemophilia B, Continue to 2
☐ Acquired von Willebrand syndrome, <i>Continue to 3</i>
Acquired hemophilia, Continue to 3
☐ Inhibitors to factor XI, <i>Continue to 3</i> ☐ Glanzmann's thrombasthenia, <i>Continue to 3</i>
☐ Other, please specify, No further questions
2. Does the patient have inhibitors? ☐ Yes, Continue to 3 ☐ No, Continue to 3
3. Is the requested medication prescribed by or in consultation with a hematologist? ☐ Yes, Continue to 4 ☐ No, Continue to 4
 4. Is the request for continuation of therapy? ☐ Yes, Continue to 8 ☐ No, Continue to 5
5. What is the diagnosis? Congenital factor VII deficiency, <i>No further questions</i> Hemophilia A with inhibitors, <i>Continue to 6</i> Hemophilia B with inhibitors, <i>Continue to 6</i> Acquired von Willebrand syndrome, <i>Continue to 7</i> Acquired hemophilia, <i>No further questions</i> Inhibitors to factor XI, <i>No further questions</i> Glanzmann's thrombasthenia, <i>No further questions</i>
6. At any point in time, has the patient had an inhibitor titer greater than or equal to 5 Bethesda units per milliliter (BU/mL)? ☐ Yes, No Further Questions ☐ No, No Further Questions
7. Have other therapies (such as desmopressin, factor VIII/von Willebrand factor [Alphanate, Humate, Wilate]) failed to control the patient's condition? Tyes, <i>No Further Questions</i> No, <i>No Further Questions</i>

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC PP - Hemo - NovoSeven RT SGM - 04/2023.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076

8. Is the patient experiencing benefit from therapy (e.g., reduced frequence ☐ Yes, <i>No Further Questions</i> ☐ No, <i>No Further Questions</i>	ey or severity of bleeds)?
= 1.6, 1.6.1 m.m.e. g.	
I attest that this information is accurate and true, and that documentation information is available for review if requested by Priority Partners.	n supporting this
X	
XPrescriber or Authorized Signature	Date (mm/dd/yy)